Neurocrine’s $2.9B Soleno Buyout Brings What Could Become Its Next Blockbuster Drug
Back to News
AlphaMaven Alternative Investment News
Hedge Fund Private Equity

Neurocrine’s $2.9B Soleno Buyout Brings What Could Become Its Next Blockbuster Drug

dealbreaker
4 months ago
156 views
Neurocrine Biosciences is expanding its scope in rare endocrine disorders through the $2.9 billion acquisition of Soleno Therapeutics, a company that commercialized the first approved drug for a rare genetic condition that leads to ravenous hunger.The Soleno drug, Vykat XR, won its FDA approval in Prader-Willi syndrome a little more than a year ago. Since its launch, the once-daily pill has seen rapid market uptake, giving San Diego-based Neurocrine confidence that the product can complement its...

Continue Reading

Sign up for FREE to read the full article and access 150K+ alternative investment headlines.

Create Free Account Login

Not a member yet?

Why AlphaMaven

The Premier Alternative
Investment Platform

Research & Due Diligence for Qualified Investors

Free Membership for Qualified Investors & Industry Participants
Personalized Content
Breaking News 24/7
Daily Newsletter & Indices
Investment Listings
Company & Contact Directory
Member Publications
Alpha University Videos
AUM Accelerator Program
Due Diligence, Webinars, Events & LeaderBoards
162K+
News & Posts
24K+
Investor Profiles
24/7
Coverage
Sign Up Now

ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.

© 2026 Maven Data Group, Inc.